Background and Aims: Anemia is a common complication of heart failure and Chronic
Kidney Disease (CKD). Sacubitril-valsartan is a novel therapy for the treatment of chronic Heart
Failure with a reduced Ejection Fraction (HFrEF). We have evaluated the short-term effects of sacubitril-
valsartan on the anemia of CRS.
Methods: The study group comprised 39 patients with HFrEF, who were followed-up for three
months. The study is a retrospective analysis of clinical data. Data of 3 months’ and baseline visits
were recorded including plasmatic creatinine, glomerular filtration rate, cystatin C, kaliemia, haemoglobin,
pro-BNP, and albuminuria.
Results: In all, 34 patients ended the follow-up. Mean sacubitril-valsartan dosage at baseline was 101
± 62 mg/day and 126 ± 59 mg/day at end. Mean hemoglobin increased from 12.2 ± 1.1 g/dl at baseline
to 12.9 ± 1.0 g/dl (p = 0.001,). Prevalence of anemia was 64.7% (95%CI, 47.9-78.5%) at baseline
and 38.4 (95%CI, 23.9-55.0%) after the follow-up (p = 0.016). Serum cystatin C levels decreased
from 2.71 ± 1.0 to 2.48 ± 1.0 mg/l (p = 0.028). Serum K levels remained unchanged (baseline
4.94 ± 0.60, three months visit 4.94 ± 0.61 mmol/l, p = 0.998).
Conclusion: Sacubitril-valsartan improves anemia in CRS patients. An improvement in serum cystatin
levels was observed. Few untoward effects were detected. These findings should be confirmed in
wider clinical trials.